Augmont Enterprises IPO Day 3: GMP Jumps to 41%, Signals Strong Listing Gains as Subscription Tops 15x

Augmont Enterprises IPO entered its final bidding day on August 25, 2026, with investor demand remaining strong. The ₹825-crore issue was subscribed 15.12 times by 10:10 AM, while its grey market premium (GMP) stood at around ₹325. That pointed to a potential 41.24% listing gain. Non-institutional investors led the demand, and investors were now watching the final subscription figure and whether the strong GMP would translate into a firm market debut.

Augmont Enterprises IPO Day 3 Subscription Status

The Augmont Enterprises IPO saw demand pick up sharply on its final bidding day. By 10:10 AM, investors had placed bids for 11.67 crore shares against 77.16 lakh shares on offer, taking the overall subscription to 15.12 times. NIIs had subscribed 35.24 times, while the retail portion stood at 14.02 times. Later intraday figures pushed the subscription above 20 times, showing that buying interest stayed high as the issue moved towards closure.

Which investor category is driving demand?

Non-institutional investors accounted for the strongest demand in the issue. Their subscription level points to high interest from high-net-worth investors and other non-retail applicants. QIB participation was more measured, although this category also moved above one-time subscription during the final session.

Augmont Enterprises IPO GMP Climbs to 41%

The Augmont Enterprises IPO GMP remained firmly positive on Day 3. At around 11:31 AM on August 25, the grey market premium was ₹325 per share, or about 41.24% above the ₹788 upper price band. Based on that GMP, the estimated grey-market listing price came to around ₹1,113.

The GMP has moved sharply during the IPO period. It was around ₹300 on August 21 before rising to ₹380 on August 23 and 24. It then eased to ₹325 on August 25. The decline from its peak shows that grey-market expectations can change quickly.

GMP remains an unofficial indicator. It does not guarantee the actual listing price or a profit.

Augmont Enterprises IPO Price, Size and Key Dates

The IPO has a ₹750 to ₹788 price band and a minimum lot size of 19 shares. At the upper price band, a retail investor needs ₹14,972 for one lot. The ₹825-crore issue includes a ₹620-crore fresh issue and a ₹205-crore offer for sale.

Key dates include:

• IPO opened: August 21, 2026
• IPO closes: August 25, 2026
• Expected allotment: August 26-27, subject to final schedule
• Expected listing: August 28 or August 31, depending on the final exchange schedule

Published schedules differ on the exact allotment and listing dates. Investors should check the final exchange announcement before taking any action.

Why are Investors Watching Augmont Enterprises?

Augmont operates across the gold and silver value chain. Its business includes bullion procurement and refining, B2B trading, digital gold, jewellery manufacturing and other precious-metals services. As of March 31, 2026, the company operated across 24 states, had more than 5,223 enterprise members and had served over 49.62 million registered digital-gold consumers through direct and alliance channels.

Augmont Enterprises plans to use IPO proceeds to expand its reach deeper into India's jewellery ecosystem.

According to Non-Executive Director Sachin Kothari, the company aims to increase its delivery-centre network from 20 to 35 locations. pic.twitter.com/iVb4bHFEey

— NDTV Profit News (@NDTVProfit) August 25, 2026

Its financial growth has also drawn attention. Revenue increased from about ₹34,949 crore in FY24 to ₹94,282 crore in FY26. During the same period, PAT rose from ₹75.97 crore to ₹348.30 crore.

What are the Main Risks Before Listing?

Strong IPO demand does not remove the company’s business risks. Augmont operates with thin margins. Its FY26 EBITDA margin was about 0.41%, while its PAT margin stood at around 0.37%. Even small changes in costs or trading conditions can affect earnings.

Gold-price movements, inventory needs, customer concentration and competition are other factors investors need to consider. The company plans to use a large share of the fresh issue proceeds for working capital, including inventory procurement and advance margin requirements.

Augmont Enterprises IPO Listing Gain Outlook

At a ₹325 GMP, the estimated price works out to around ₹1,113. That represents a potential 41.24% premium over the ₹788 issue price. This remains a grey-market estimate, not a guaranteed listing price.

The actual debut will depend on market sentiment, investor demand and broader market conditions on the listing day.

What Do Analysts Say About Augmont Enterprises IPO?

Anand Rathi Research has given the IPO a “Subscribe for Long Term” rating. Its research points to Augmont’s brand, distribution network, refining capacity and digital ecosystem. It also noted that the IPO looks fully priced at around 20.6x annualised FY26 P/E.

Ventura Securities and BP Equities have also taken positive views on the issue, while pointing to valuation and operating risks.

Short stock outlook and technical view

Augmont Enterprises is still an IPO rather than a listed stock, so standard technical indicators such as moving averages, RSI and support levels are not available yet. For now, subscription momentum and GMP provide the main market signals.

An AI stock analysis tool can become more useful after the listing, once enough price and volume data is available to assess technical trends.

Conclusion

Augmont Enterprises is heading into the close of its IPO with heavy subscription demand and a GMP of around 41%. The company has reported strong revenue and profit growth, but its thin margins, working-capital needs and valuation deserve attention. The current GMP suggests strong listing expectations, yet it remains only a grey-market signal. Investors should review the company’s fundamentals before relying on the expected listing gain.

Disclaimer:

The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.